logo
Meera Syal: When Dad mistook me for Mum, I played along not to upset him

Meera Syal: When Dad mistook me for Mum, I played along not to upset him

Yahooa day ago

The fact that there isn't even a word in the Punjabi language that means 'dementia' says a lot about the stigma and ignorance surrounding the disease in Indian communities. And yet ironically, incidences of Alzheimer's are much higher in minority ethnicgroups compared to white people. So as a group, we are actually more at risk – and yet we know less.
In Asian communities, when signs of memory loss are apparent, it's often just dismissed as old age: 'They're forgetful,' people say. Or 'their minds are going.' But actually there's a huge difference between just age-appropriate forgetfulness and signs of this critical disease. My father, Surendra, really was the most wonderful dad – very loving, playful, sociable, and he adored music. Our house in Walsall, where I grew up, was always full of people singing.
Originally a philosophy graduate, Dad worked as an accountant for years in order to provide for our family, my mum Surinder, me and my brother Rajeev, who is seven years younger than me. He was a very bright man who had endured great hardship as a refugee from the partition in 1947, when the British government withdrew from India.
Dad's entire family had to abandon their home and flee across the border, so he started from literally nothing and became a self-made man. I'm sure all the stresses he'd suffered going through immigration – and then adaptation – made him more vulnerable to Alzheimer's eventually.
It wasn't until 2012 when it became clear to me that Dad wasn't himself. By then I'd long been living in London, as a writer and actor and with two children of my own. Mum had known Dad was unwell for some time, but she had been coping on her own, silently soldiering on for a couple of years before we knew. It started with forgetting where he was driving, the familiar routes he'd taken for years seemed lost.
Then in crept a level of paranoia, he became suspicious of even friends he'd known for years. Some days he'd momentarily forget my Mum. Worried, Mum had taken him to the memory clinic several times, but Dad just kept passing the tests, 'maybe because he was having a good day,' she admitted in hindsight. Later, we found out those tests aren't immensely accurate for diagnosing certain different forms of dementia, and actually the only way you can tell is by having a brain scan.
In reality, trying to get a brain scan on the NHS is a long and torturous process. You really have to stand your ground and say 'I know something's wrong – and yes he may have passed the memory test – but I know that something is not right.'
Ultimately, it was two or three years before Dad's diagnosis was confirmed. That was a long time for my mother to be struggling alone. It must have been isolating. And in that time he could have been taking medication that might have at least been able to help manage his symptoms. Early diagnosis is so crucial.
By 2012, Mum could no longer hide it from us or anyone in the wider community. Intervention was needed. Initially we arranged for a carer to come to their home, but that didn't go well as Dad didn't trust them. He didn't want them in the house. And then he kept leaving the house, which meant we had to have security locks fitted to try and keep him safe. He was always restless, and this agitation was hard to live with.
Then he became a security risk. One of the cruellest things about this disease is how it affects people's personalities. Becoming ruder or cruder is common with certain types of dementia. Everyone is different so it's impossible to predict. Some people can becalm and vacant, while others become very verbose and front-footed.
While Dad was never aggressive, the paranoia was hard, and it was painful when he started insisting Mum had been replaced by a stranger. At that stage we realised we couldn't cope at home, not with Dad escaping, and Mum not being able to keep him safe.
For me the worst part was this intermediate stage, when the disease came in and out, because there were times when Dad was completely lucid and cogent and wanted to know what was happening, when he knew something was wrong. This is when families really need support from places like the Alzheimer's Society, because how do you know how to have that conversation with a loved one who is confused and frightened? How do you say the right thing? They have trained, experienced people who can advise you on those difficult talks.
What I learnt was that one of the biggest mistakes people make – quite understandably – is trying to correct someone when they are in their own version of reality. Saying to them things like 'No, that's not right' or 'you did that yesterday, remember?' actually distresses a loved one more, because they're coping with two or three different realities in their heads. Instead, it's better to enter into their world with them, even if that means playing along that you are their long-lost friend.
Dad would often think I was my mother when she was younger, instead of his daughter. So I'd go along with that as it calmed and reassured him. That has to be the aim. Sometimes, five minutes later after he'd stopped being distressed, he'd find his own way back and know who I was.
I came to believe that actually, there are many different kinds of reality in life. I mean, how do we know who's in the right one? Him or me? It becomes quite a Matrix kind of question! I had to open my mind a little bit to try and find the understanding and compassion – and go with whatever he was giving me.
When a loved one has dementia it's a long, slow goodbye. You're losing them bit by bit. It's like a little light going off gradually, or a mechanism winding down. You become the parent, not the daughter. While that is certainly awful, there can be many moments of joy along the way, when the light is still on.
For Dad, the thing that never left him until the very end, was his passion for music. He loved ghazals, Indian poetry and ballads, which we played and he would sing along. We also put old films from the 1950s and 60s from his youth on the iPad, essentially making our own memory pack for him. Photographs and anything that keeps the memories and the connections going is useful. Dad always had a great sense of humour, so we tried to make him laugh, and be upbeat.
Mum visited my dad in the care home every single day and they had a routine, where they'd practise throwing and catching a ball (to keep up his motor skills) and then look at old photos together. You find your own ways of connecting, but the Alzheimer's Society is an amazing resource of information and advice, and through the Dementia Friends network, we found incredible volunteers who would even offer to give relatives a break by sitting and talking to your loved one.
Dad was in the care home for six years, so it became the new normal in some ways. You learn to live with the upset, but I hated that in their golden years, when they should have been growing old together, they were separated, with Dad remaining in the home until he died in 2018.
When I remember my Papa, I don't try to forget his illness; you can't, it's part of the journey we all had together. I just hope we did everything we could to make his quality of life as good as we could in those last years. You reach a stage where it's actually worse for the family than it is for the person with the disease, because they're in their own world.
I took advice about genetic testing, but looking at the rest of my family history, it's highly unlikely to be genetic. There's no history of dementia on my father's side, his older brother is still alive and well, his own father died in his mid-nineties unaffected by dementia. My mother's own mum died at the grand age of 103 (in India!) and she has sisters who are still alive with all their faculties.
Losing my parents has made me more health conscious. I'm alert to the increased risks in South Asians of hypertension, obesity, diabetes, and cardiovascular health. And actually there's now more awareness of the massive link between gum disease and Alzheimer's. My father suffered with terrible gums for many, many years.
The older I get I take better care of myself, watching my cholesterol levels and cardiovascular health and I regularly exercise and look after my gums with hygienist appointments three times a year. I can't change my genetic hand down, but I can try my best with my lifestyle to try and prevent my kids going through this with me one day.
As told to Susanna Galton
Meera Syal CBE is an Ambassador for Alzheimer's Society and is supporting the charity's appeal. Donate at alzheimers.org.uk/telegraph
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New Analysis Finds Dementia Caregivers More Likely to Report Modifiable Risk Factors That Increase Their Own Risk for Dementia
New Analysis Finds Dementia Caregivers More Likely to Report Modifiable Risk Factors That Increase Their Own Risk for Dementia

Yahoo

timean hour ago

  • Yahoo

New Analysis Finds Dementia Caregivers More Likely to Report Modifiable Risk Factors That Increase Their Own Risk for Dementia

– Dementia caregivers under age 45 are particularly vulnerable for having modifiable risk factors for dementia – CHICAGO, June 12, 2025 /PRNewswire/ -- A new analysis finds nearly 60% of dementia caregivers report having at least one modifiable risk factor that could increase their own chances of developing dementia. Nearly one in four caregivers (24.3%) report having multiple risk factors. This first-of-its-kind analysis found that dementia caregivers are significantly more likely than the general population to experience conditions such as obesity, diabetes, poor sleep, smoking and hypertension. The most pronounced differences were seen in smoking (caregivers were 30% more likely), hypertension (27% more likely), and poor sleep (21% more likely). Additionally, caregivers were 12% more likely to have diabetes and 8% more likely to be obese. Physical inactivity was the only one of the six modifiable risk factors examined for which dementia caregivers reported being less likely to engage in than the general population (9% less likely). "This analysis underscores the vulnerability of dementia caregivers," said Matthew Baumgart, senior vice president, Health Policy, Alzheimer's Association. "Dementia caregivers are often so busy caring for a family member or friend that they overlook their own health. This analysis should be a wake-up call for public health to develop strategies that address caregiver health to help this at-risk population." The analysis, conducted by the Public Health Center of Excellence on Dementia Risk Reduction at the Alzheimer's Association and the Public Health Center of Excellence on Dementia Caregiving at the University of Minnesota, found that younger dementia caregivers (under age 45) are particularly vulnerable to having modifiable risk factors for dementia. It found: Younger dementia caregivers are 40% more likely to have multiple risk factors (21.6% versus 15.5%) compared with all adults in their age group. Younger dementia caregivers were also 86% more likely to smoke, 46% more likely to have hypertension, and 29% more likely to report less than 6 hours of sleep per night on average compared with all adults in their age group. "By identifying elevated risk factors for dementia among certain dementia caregiving populations compared with the overall population, public health policymakers can prioritize and tailor resources and interventions accordingly," Joseph Gaugler, Ph.D., University of Minnesota School of Public Health. "Younger dementia caregivers, as well as American Indian/Alaska Native, Black, and male dementia caregivers, are all distinctly more likely to have conditions or behaviors that put them at greater long-term risk for cognitive decline and could benefit from additional attention." Previous studies have shown that caring for a person with Alzheimer's disease or another dementia can create new, or worsen existing, health problems for caregivers. More than 1 in 3 dementia caregivers say their health has gotten worse due to their care responsibilities, and more than a quarter of dementia caregivers delay or do not do things they should to maintain their health. The new analysis aims to spur public health agencies to address caregiver health and reduce the risk of dementia among caregivers. The new analysis examined data from the 2021-2022 Behavioral Risk Factor Surveillance System (BRFSS) to determine if dementia caregivers are more likely than the general population to have modifiable risk factors associated with dementia. Caregiving data from 47 states were included in the analysis. This work is supported by the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health and Human Services (HHS) as part of financial assistance awards totaling $6,307,435 with 100 percent funded by CDC/HHS. The contents are those of the Alzheimer's Association and the University of Minnesota and do not necessarily represent the official views of, nor an endorsement by, CDC/HHS, or the U.S. Government. About the Public Health Center of Excellence on Dementia Risk ReductionThe Public Health Center of Excellence on Dementia Risk Reduction translates the latest science on dementia risk reduction into actionable tools, materials and messaging that public health agencies can use. For more information visit or email CenterofExcellence@ About the Public Health Center of Excellence on Dementia CaregivingThe Public Health Center of Excellence on Dementia Caregiving offers technical guidance to, curates and distributes resources for, and brings together public health agencies, service organizations, healthcare providers, and dementia caregivers. For more information visit View original content to download multimedia: SOURCE Alzheimer's Association Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

Business Wire

timean hour ago

  • Business Wire

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary, Ph.D., executive vice president and chief development officer, will retire effective January 2026 and that Holly Kordasiewicz, Ph.D., currently senior vice president, neurology, will succeed him in the role. 'Richard has made tremendous contributions to Ionis over his 30-year tenure during which he spearheaded dozens of development programs and brought six innovative medicines through regulatory approvals, including TRYNGOLZA, our first independent commercial medicine. We thank him for his leadership and unwavering dedication to patients in need,' said Brett P. Monia, Ph.D., chief executive officer, Ionis. 'Holly is a deeply respected and innovative leader who will champion our vision to bring a steady cadence of transformational medicines to people in need and support Ionis' continued growth as a fully integrated biotechnology company. Her broad experience across research and development, strong operational and management skills, and deep neurology expertise, position Holly to successfully guide our portfolio, which includes eight wholly owned neurology medicines in clinical development.' Dr. Kordasiewicz has 20 years of experience in research and development and joined Ionis in 2011. An expert in neurology drug development, she currently oversees Ionis' industry-leading neurology program, including medicines for Alexander disease, Angelman syndrome, Alzheimer's disease, prion disease and multiple system atrophy. Dr. Kordasiewicz also played an integral role in the discovery and development of our Biogen-partnered programs QALSODY ® (tofersen) for a genetic form of amyotrophic lateral sclerosis and IONIS-MAPT Rx (BIIB080), a promising Alzheimer's disease medicine in Phase 2 development. Dr. Kordasiewicz holds a B.A. from SUNY-Geneseo and a Ph.D. in Neuroscience from the University of Minnesota. She completed postdoctoral work at the University of Minnesota and the University of California San Diego. Dr. Geary joined Ionis in 1995 and has been involved in nearly every aspect of discovery and development. Under Dr. Geary's leadership, Ionis submitted more than 50 investigational new drug applications to regulatory agencies and achieved six FDA and EU approvals, including TRYNGOLZA ® (olezarsen). Dr. Geary will serve as a strategic consultant to Ionis throughout 2026​ to support a seamless transition. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit and follow us on X (Twitter), LinkedIn and Instagram. Ionis Forward-looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of our commercial medicines, additional medicines in development and technologies. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2024, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company. In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our" and "us" all refer to Ionis Pharmaceuticals and its subsidiaries. Ionis Pharmaceuticals ® and TRYNGOLZA ® are trademarks of Ionis Pharmaceuticals, Inc. QALSODY ® is a registered trademark of Biogen.

Cognito's Spectris AD slows Alzheimer's disease progression in trial
Cognito's Spectris AD slows Alzheimer's disease progression in trial

Yahoo

time2 hours ago

  • Yahoo

Cognito's Spectris AD slows Alzheimer's disease progression in trial

Cognito Therapeutics has reported outcomes from a post hoc analysis of its OVERTURE feasibility trial, indicating that the investigational Spectris AD therapy can slow the progression of Alzheimer's disease. The device utilises non-invasive neuromodulation with synchronised light and sound at a gamma frequency to restore disrupted brain activity in Alzheimer's patients. The study involved 76 mild-to-moderate affected subjects. It included a randomised six-month controlled phase and a subsequent 12-month open-label extension. During the controlled phase, one-hour treatments with the device daily led to 4.83 months of preserved daily activity, 4.56 and 4.09 months of delayed cognitive decline and whole-brain atrophy, respectively. Subjects who received the device's treatment showed a delay in progression of the disease compared to those in the sham treatment group. Specifically, subjects initially assigned to Spectris AD and later treated with SPECTRIS in the open-label extension study showed a slower progression to the same degree of decline that the sham group experienced during six months. Tailored for at-home use, Spectris AD has been granted breakthrough device designation by the US Food and Drug Administration (FDA) and is now under assessment in the HOPE pivotal trial. Cognito Therapeutics CEO Christian Howell said: 'Our brains are electrical systems, and Alzheimer's disrupts the rhythms that govern memory, cognition, and our ability to function. 'Spectris AD represents a new class of therapy, one based in physics, that restores these natural neural oscillations without relying on a chemistry-based pharmacologic therapy. These findings show the potential to meaningfully slow disease progression by leveraging the potential of neuromodulation.' Last year, Cognito enrolled the first subject in a biomarker substudy within the HOPE trial evaluating the sensory stimulation device in Alzheimer's patients. "Cognito's Spectris AD slows Alzheimer's disease progression in trial" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store